Impact of Type of Hypomethylating Agent (HMA) Used on Outcomes of Patients (Pts) with Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) - a Large, Multicenter, Retrospective Analysis

被引：0

作者：

Bewersdorf, Philipp ^{[1
,2
]}

Kewan, Tariq ^{[3
]}

Blaha, Ondrej ^{[4
,5
,6
]}

Stahl, Maximilian ^{[7
]}

Al Ali, Najla H. ^{[8
]}

DeZern, Amy E. ^{[9
]}

Sekeres, Mikkael A. ^{[10
]}

Uy, Geoffrey L. ^{[11
]}

Carraway, Hetty E. ^{[12
]}

Desai, Pinkal ^{[13
]}

Griffiths, Elizabeth A. ^{[14
]}

Stein, Eytan M. ^{[15
]}

Brunner, Andrew M. ^{[16
]}

McMahon, Christine M. ^{[17
]}

Zeidner, Joshua F. ^{[18
]}

Savona, Michael R. ^{[19
]}

Stempel, Jessica M. ^{[20
]}

Chandhok, Namrata Sonia ^{[21
]}

Ramaswamy, Rahul ^{[22
]}

Roboz, Gail J. ^{[23
]}

Rolles, Benjamin ^{[24
]}

Wang, Eunice S. ^{[14
]}

Harris, Amyah C. ^{[25
]}

Amaya, Maria L. ^{[26
]}

Hawkins, Hayley ^{[27
]}

Grenet, Justin ^{[28
]}

Gurnari, Carmelo ^{[29
]}

Shallis, Rory M. ^{[30
]}

Xie, Zhuoer ^{[31
]}

Maciejewski, Jaroslaw P. ^{[29
]}

Sallman, David A. ^{[31
]}

Della Porta, Matteo Giovanni ^{[32
]}

Komrokji, Rami S. ^{[8
]}

Zeidan, Amer M. ^{[33
,34
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY USA

[2] Yale Univ, Sect Hematol, Dept Med, New Haven, CT USA

[3] Yale Univ, Sect Hematol, Dept Internal Med, New Haven, CT USA

[4] Yale Univ, Sch Publ Hlth, Dept Biostat, New Haven, CT USA

[5] Yale Univ, Sch Publ Hlth, Yale Ctr Analyt Sci, New Haven, CT USA

[6] Yale Univ, Yale Canc Ctr, New Haven, CT USA

[7] Dana Farber Inst, Boston, MA USA

[8] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA

[9] Johns Hopkins Univ, Baltimore, MD USA

[10] Univ Miami, Sylvester Canc Ctr, Miami, FL USA

[11] Washington Univ, Div Oncol, Sch Med, St Louis, MO USA

[12] Cleveland Clin, Taussig Canc Inst, Dept Hematol & Med Oncol, Leukemia Program, Cleveland, OH USA

[13] Weill Cornell Med, New York, NY USA

[14] Roswell Park Comprehens Canc Ctr, Buffalo, NY USA

[15] Mem Sloan Kettering Canc Ctr, Leukemia Serv, New York, NY USA

[16] Dana Farber Canc Inst, Div Hematol Oncol, Boston, MA USA

[17] Univ Colorado, Div Hematol, Sch Med, Aurora, CO USA

[18] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA

[19] Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Med Ctr, Nashville, TN USA

[20] Yale Sch Med, Sect Hematol, Dept Internal Med, New Haven, CT USA

[21] Univ Miami, Div Hematol, Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL USA

[22] Washington Univ, St Louis, MO USA

[23] New York Presbyterian Hosp, New York, NY USA

[24] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA USA

[25] Dana Farber Canc Inst, Boston, MA USA

[26] Univ Colorado, Div Hematol, Aurora, CO USA

[27] Vanderbilt Univ, Med Ctr, Nashville, TN USA

[28] Weill Cornell, New York, NY USA

[29] Cleveland Clin, Taussig Canc Inst, Dept Translat Hematol & Oncol Res, Cleveland, OH USA

[30] Yale Univ, Yale Sch Med, Sect Hematol, Dept Internal Med, New Haven, CT USA

[31] H Lee Moffitt Canc Inst, Tampa, FL USA

[32] IRCCS, Ctr Canc, Humanitas Res Hosp, Milan, Italy

[33] Yale Canc Ctr, Dept Internal Med, New Haven, CT USA

[34] Smilow Canc Hosp, New Haven, CT USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-178728

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：8

共 50 条

[31] The STIMULUS Program: Clinical Trials Evaluating Sabatolimab (MBG453) Combination Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) or Acute Myeloid Leukemia (AML)
Zeidan, Amer M.
Esteve, Jordi
Giagounidis, Aristoteles
Kim, Hee-Je
Miyazaki, Yasushi
Platzbecker, Uwe
Schuh, Andre C.
Sekeres, Mikkael A.
Westermann, Jorg
Xiao, Zhijian
Malek, Kamel
Scott, Jeffrey
Niolat, Julie
Peyrard, Severine
Ma, Fei
Kiertsman, Flavia
Stegert, Mario
Hertle, Sabine
Fenaux, Pierre
Santini, Valeria
BLOOD, 2020, 136
[32] Impact of Transformation to Acute Myeloid Leukemia (AML) on Overall Survival (OS) among Patients with Higher-Risk Myelodysplastic Syndromes (HR-MDS) in the United States of America (USA)
Kota, Vamsi
Ogbonnaya, Augustina
Farrelly, Eileen
Schroader, Bridgette
Kristo, Fjoralba
Raju, Aditya
Dalal, Mehul
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S348 - S348
[33] Characteristics and Outcomes of Younger Adult Patients (Pts) with Myelodysplastic Syndromes (MDS): A Multicenter Retrospective Study
Abaza, Yasmin
Xie, Zhuoer
Burkart, Madelyn
Badar, Talha
Desai, Pinkal
Shallis, Rory M.
Patel, Anand Ashwin
Cohen-Nowak, Adam
Oh, Timothy S.
Walker, Chelsea
Easwar, Neela
Kewan, Tariq
Cannova, Joseph
Bell-Burdett, Kirsten
Al Ali, Najla H.
Sallman, David A.
Roboz, Gail J.
Carraway, Hetty E.
Zeidan, Amer M.
Patnaik, Mrinal M.
Altman, Jessica K.
Komrokji, Rami S.
BLOOD, 2023, 142
[34] Immune and Epigenetic Landscape of TP53-mutated Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes (HR-MDS)
Zeidan, Amer M.
Philipp, Jan
Bewersdorf, Philipp
Hasle, Vanessa
Thompson, Ethan G.
de Menezes, Daniel Lopes
Rose, Shelonitda
Boss, Isaac
Fox, Brian
BLOOD, 2021, 138
[35] Treatment Utilization and Characteristics Among Patients with Higher-Risk Myelodysplastic Syndromes According to Hypomethylating Agent Use
Zeidan, Amer M.
Divino, Victoria
DeKoven, Mitch
Shah, Drishti
Wang, Elizabeth
Bey, Dawn
Salimi, Tehseen
Epstein, Robert S.
BLOOD, 2021, 138
[36] HOSPITALIZATION AND EMERGENCY ROOM VISITS AMONG PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES BY HYPOMETHYLATING AGENT USE
Zeidan, A. M.
Joshi, N.
Kale, H.
Wang, W. -J.
Corman, S.
Hill, K.
Salimi, T.
Epstein, R.
LEUKEMIA RESEARCH, 2021, 108 : S26 - S26
[37] Outcome Of Patients (pts) With Low and Intermediate-1 Risk Myelodysplastic Syndrome (MDS) After Hypomethylating Agent (HMA) Failure
Jabbour, Elias
Garcia-Manero, Guillermo
Xiao, Lianchun
Najla, Al Ali
Mishra, Asmita
Padron, Eric
Lancet, Jeffrey E.
Bryan, Jeffery
Prescott, Hillary
Steensma, David P.
Sekeres, Mikkael A.
Roboz, Gail J.
List, Alan
Kantarjian, Hagop M.
Komrokji, Rami S.
BLOOD, 2013, 122 (21)
[38] Magrolimab Alters the Tumor Microenvironment to Improve Bone Marrow Functions in Patients With Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes (HR-MDS)
Johnson, Lisa
Zhang, Yajia
Su-Feher, Linda
Lee, Yeonju
Sallman, David A.
Asch, Adam S.
Al Malki, Monzr M.
Kim, Hyunjae Ryan
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S368 - S369
[39] Direct Medical Costs Associated With Treatment Nonpersistence in Patients With Higher-Risk Myelodysplastic Syndromes Receiving Hypomethylating Agents: A Large Retrospective Cohort Analysis
Joshi, Namita
Kale, Hrishikesh
Corman, Shelby
Wert, Tim
Hill, Kala
Zeidan, Amer M.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (03): : E248 - E254
[40] Impact of Hypomethylating Agent Use on Hospital and Emergency Room Visits, and Predictors of Early Discontinuation in Patients With Higher-Risk Myelodysplastic Syndromes
Zeidan, Amer M.
Joshi, Namita
Kale, Hrishikesh
Wang, Wei-Jhih
Corman, Shelby
Salimi, Tehseen
Epstein, Robert S.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (09): : 670 - 679

← 1 2 3 4 5 →